Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CYWIX
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-CD74 ADC 9-4
|
|||||
| Synonyms |
Anti-CD74 ADC 12-10
Click to Show/Hide
|
|||||
| Organization |
Merck & Co., Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 3 Indication(s)
Diffuse large B-cell lymphoma [ICD11:2A81]
Investigative
Renal cell carcinoma [ICD11:2C90]
Investigative
Sezary syndrome [ICD11:2B02]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
Anti-hCD74 LL1
|
Antibody Info | ||||
| Antigen Name |
HLA class II histocompatibility antigen gamma chain (CD74)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Anti-CD74 ADC 9-4 linker
|
|||||
| Conjugate Type |
The drug linker was conjugated to the unnatural amino acid (UAA) para-azido phenylalanine (p-AF)
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 0.20 ug/mL | Positive CD74 expression (CD74 +++/++) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
|
||||
| In Vitro Model | T lymphocytic leukemia | HuT 78 cells | CVCL_0337 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | 0.21 ug/mL | Positive CD74 expression (CD74 +++/++) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | SU-DHL-6 cells | CVCL_2206 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 30.00 ug/mL | Negative CD74 expression (CD74 -) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
|
||||
| In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.